Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$17.75 USD
+1.61 (9.98%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $17.80 +0.05 (0.28%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
Tyra Biosciences, Inc. [TYRA]
Reports for Purchase
Showing records 1 - 20 ( 35 total )
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Data 2H24; 2023 Financials; Adding HCH to Model - Raising PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Rare Pediatric Disease Designation For TYRA-300 Enables Path to PRV; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Layering in the PIPE; Favorable Setup into Initial TYRA-300 Data
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Dose Escalation; 2024 Data; TYRA-200 Dosing Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TYRA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-200 Dosing to Begin by YE23; 3Q23 Financials; Modulating PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D